NEURODYN LIFE SCIENCES INC has a total of 21 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2008. It filed its patents most often in EPO (European Patent Office), China and United States. Its main competitors in its focus markets pharmaceuticals, environmental technology and organic fine chemistry are BOMSUND GRUPO ASESOR SL, REVAAX PHARMACEUTICALS LLC and TERADA HIROSHI.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | China | 3 | |
#3 | United States | 3 | |
#4 | Canada | 2 | |
#5 | Hong Kong | 2 | |
#6 | Japan | 2 | |
#7 | WIPO (World Intellectual Property Organization) | 2 | |
#8 | Australia | 1 | |
#9 | India | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Environmental technology | |
#3 | Organic fine chemistry | |
#4 | Biotechnology |
# | Name | Total Patents |
---|---|---|
#1 | Maelicke Alfred | 15 |
#2 | Kay Denis G | 4 |
#3 | Alfred Maelicke | 2 |
#4 | Maclellan Alexander | 1 |
#5 | Mclellan Alexander | 1 |
Publication | Filing date | Title |
---|---|---|
HK1257737A1 | Use of gln-1062 salt in the preparation of a drug for treating brain diseases related to cognitive disorders | |
WO2018148821A1 | Composition and method for improving cognitive function and brain bioavailability of ginseng and ginsenosides and treating neurodegenerative disease and neurological disorders | |
CA2958117A1 | Composition and method for improving cognition and brain bioavailability of ginseng and ginsenosides and treating neurodegenerative disease and neurological disorders | |
AU2013294917A1 | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs | |
EP3009143A1 | Progranulin for use in treating parkinson's disease or alzheimer's disease | |
CN102007129A | Derivatives of galantamine as pro-drugs for the treatment of human brain diseases |